Analyst Price Target is $5.25
▲ +31.25% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $5.25, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 31.25% upside from the last price of $4.00.
Current Consensus is
Reduce
The current consensus among 3 contributing investment analysts is to reduce stock in Prelude Therapeutics. This Reduce consensus rating has held steady for over two years.
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Read More